Thank you very much, Daniel, and it's great to be here again, totally concur with Daniel, we're at the latter stages of the final investment decision that leads to the construction of the facility and the funding. We're also at the later stages of the funding requirement that we need. Those are obviously the home runs that we've been working on over the last couple of months, and they've been the top priorities. While those have hit the home runs, we've been looking at base hits as well, and we have a lot of successful endeavors that we have there, which we'd love to communicate to you.
If you have the analyst package in front of you, I'd love for you to turn to the P&L, which is Page 2 of the document. And there, you'll look at the results for the quarter. Ordinarily, negatives are -- mean not good news, but not in our case because the negatives are implying that the expenses are way down versus last year. Not only are they're way down, they're way down across the board. Every single caption has a negative the only one that doesn't is foreign exchange, which we can't control foreign exchange gyrations between the Canadian and U.S. dollar. So expense reductions across the board and not only expense reductions, significant ones.
And we're talking about -- I mean, in the R&D function, we're talking about reductions to the tune of 46%, just under the 50% threshold. On the G&A, we're talking about a 30% reduction in expenses largely driven by lower professional fees, half the amount comes from lower professional fees. So we've looked in concert with other department heads. We've looked at every item where we can streamline operations where we can improve productivity, really looking at what is discretionary and what is necessary. And I'm very, very proud that overall, our expenses have come down to the tune of 40% this quarter over last quarter.
So that's good. And another testament to a lot of the finance things that we've been working on is, do you see this one line interest income where last quarter, we had $10,000 and now we've got $219,000. So we're not resting on our laurels by having a significant cash position. We're deploying it in highly liquid market instruments and actually benefiting from inverted yield curve and inverted yield curve benefits savers on the short end and borrowers at the long end. We happen to be door #1.
So we're coming about at all angles. What I guided the market, if you guys remember correctly last quarter was a cash burn rate, which I define as look at our cash burn rate from our P&L excludes stock-based compensation because it's noncash, exclude depreciation on property, plant and equipment because it's not cash, same thing with the intangible asset. And then back out the items that are going to be recoverable from the joint venture, we've been spending a lot of time, money, equipment, internal costs, external costs, and we shoulder them on our financial statements, but we are going to get them back.
And the cash run rate for the current quarter is $4.1 million, which amounts about $1.36 million per month. Proceeding from here and given all of the streamlining opportunities that we have, and we're confident to deliver our run rate for the balance of 2024 is going to be between $1 million and $1.2 million. So I still feel very comfortable. I was guiding towards a $15 million run rate for fiscal 2024. I think we're actually going to get there for full year 2024, not land at there because just the $1 million to $1.2 million is implying kind of $6 million to $7.5 million of back office expenses.
So we are really, really in good stead of controlling costs, being smart about it, continuing to feed our innovation pipeline and making sure that we have the liquidity that we need to get to the operation of the Ulsan plant. If we turn to the balance sheet, which is 2 pages later, you see we've got about $13.4 million of cash and another $1 million of restricted cash, so let's call it $14 million. If I can tender to the accounting bonds, I would have had a receivable of about $16 million from the joint venture from SK, which we expect to be recoverable in the next fiscal cycle, sometime in 2024.
So between the $16 million and the $14 million, we've got $30 million of liquidity that we can use in the service of paying our fixed office expenses until such time that we got the plant and Ulsan running will be able to get some royalties with a little luck some dividend and then we'll be pretty much self-sufficient. So we're well advanced on our path towards self-sufficiency. And right now, with the cash on hand, with the recoverable from the joint venture from the Asia JV. We have about 3 years of liquidity on hand, which is exactly the same time frame that we need to generate funds and return on investments from the plant.
So we are really, really good financial stead. We are in good liquidity stead. We are never going to stop looking at ways that we can work better. That's something that's in our DNA. And -- but for right now, I just wanted to communicate to everybody that the financial streamlining of the expenses is largely done and will continues to be done and we're in really good financial stead from a liquidity perspective.
With that, I will turn it over to questions.